Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer - PubMed
3 months ago
- #breast cancer
- #premenopausal women
- #targeted therapy
- Younger premenopausal women (<40 years) with ER-positive early-stage breast cancer have poorer outcomes compared to older women.
- Age-related disparities are linked to distinct biological and genomic features like copy number alterations and unique immune microenvironments.
- Endocrine therapy is the cornerstone of treatment, with evolving strategies including ovarian function suppression (OFS) and CDK4/6 inhibitors.
- Molecular profiling is increasingly important in guiding treatment decisions for younger women with ER-positive breast cancer.
- Future trials should prioritize biology over age, incorporate OFS as standard-of-care, and expand biomarker-driven approaches.
- A genomically and immunologically informed strategy is essential to improve outcomes in this under-represented population.